Citations

Institution: Mayo Clinic Clear

Showing 10 of 108094 citations.

The evolving landscape of thyroid eye disease: present and future
Toro-Tobón, David , Stan, Marius N.

European Journal of Endocrinology | August 3, 2025 | Volume: 193 | Issue: 2 | Pages: R15-R24

10.1093/ejendo/lvaf156 | PMID 40794607 Get It

Abstract Thyroid eye disease (TED) is a complex ocular autoimmune disorder primarily associated with Graves’ disease. It leads to significant morbidity due to orbital inflammation, fibrosis, and tissue expansion. While corticosteroids have been the traditional mainstay of therapy, recent advancements in understanding TED pathophysiology have driven the development of targeted treatments. Notably, inhibition of the insulin-like growth factor-1 receptor with teprotumumab has revolutionized TED management, demonstrating efficacy in reducing proptosis and disease severity. Additional emerging therapies, including neonatal Fc receptor inhibitors, thyroid-stimulating hormone receptor blockers, and interleukin-6 receptor antagonists, offer promising alternatives for patients with active and refractory disease. Despite these advancements, challenges remain in disease classification and outcome assessment. As the landscape of TED management continues to evolve, this review provides a comprehensive overview of current and emerging therapies for TED, critically examines gaps in disease evaluation, and highlights the evolving paradigm of patient-centered care. Future efforts should focus on optimizing therapeutic algorithms, refining risk stratification models, guiding personalized treatment, and promoting a multidisciplinary approach, which remain essential in improving outcomes and quality of life for affected individuals.
An immunohistochemical germinal center B-cell dark zone signature identifies Burkitt lymphoma and molecular high-grade B-cell lymphomas
Zhao, Xiaoxian , Balmaceda, Alexandra, Abiera, Via S, Garber, Desiree, Rosenblum, Lynne S. , Scott, David W. , Rimsza, Lisa M. , Hsi, Eric D.

American Journal of Clinical Pathology | August 3, 2025 | Volume: 164 | Issue: 4 | Pages: 559-566

10.1093/ajcp/aqaf074 | PMID 40753450 Get It

Abstract Objective We hypothesized that a set of immunohistochemistry (IHC) stains could be used to distinguish Burkitt lymphoma (BL), the quintessential B-cell lymphoma with a germinal center B-cell (GCB) dark zone (DZ) expression signature, from diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS). This might also be applicable to high-grade B-cell lymphomas (HGBCLs) with MYC and BCL2 rearrangements (double-hit lymphomas [DHLs]) and triple-hit lymphomas (THLs). Methods A 5-marker IHC algorithm was designed from gene lists that distinguish physiologic DZ from light zone GCBs. Results In training and validation cohorts, we distinguished BL from DLBCL, NOS with high sensitivity and specificity. Because DHLs/THLs are enriched for the gene expression DZ signature (DZsig), we evaluated 19 DHLs/THLs and 4 HGBCLs, NOS. Most (83%) cases were IHC DZ. The NanoString DLBCL90 assay was performed on 34 cases to correlate IHC DZ results with the molecular DZsig. The IHC DZ call was significantly associated with the DZsig (P = .0011). The sensitivity and specificity of IHC to recognize DZsig+ cases among DLBCL, NOS and DHLs with BCL2 rearrangements/THLs were 91% and 100%, respectively. Conclusions The IHC DZ algorithm can support a diagnosis of BL and identifies MYC-BCL2 DHLs/THLs with a molecular DZsig.
A Nine‐Nucleotide Insertion Causes the Novel HLA‐C*06:402 Allele in a Family Detected by Next‐Generation Sequencing
Du, Zeying , Murrin, Michelle E., Kendrick, Jasmine R., Williams, C. D. H., Elrefaei, Mohamed , Williams, Charles D, Du, Zeying , Kendrick, Jasmine R., Williams, Charles D.

HLA | August 2, 2025 | Volume: 106 | Issue: 2 | Pages: No page available

10.1111/tan.70352 | PMID 40751401 Get It

ABSTRACTHLA‐C*06:402 differs from HLA‐C*06:02:01:01 by a nine‐nucleotide (TCCTGGCTG) insertion in exon 5.
Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy
Dhakal, Binod , Akhtar, Othman Salim , Jensen, Alexandria , Banerjee, Rahul , Friend, Reed, Martinez, Mariola Alejandra Vazquez, Wagner, Charlotte B , Davis, James A. , Afrough, Aimaz , Bhutani, Manisha , Freeman, Ciara L. , Mikkilineni, Lekha , Raza, Shahzad , Anderson, Larry D. , Kapoor, Prashant , Hosoya, Hitomi , Gaballa, Mahmoud , Midha, Shonali , Alsina, Melissa , Sborov, Douglas W. , Patel, Krina K. , Lin, Yi , Ferreri, Christopher J. , Kumar, Anupama, Cowan, Andrew J., Sidana, Surbhi , Jensen, Alexandria , Banerjee, Rahul , Friend, Reed , Vazquez-Martinez, Mariola A , Wagner, Charlotte , Davis, James A , Castaneda Puglianini, Omar , Dima, Danai , Bhutani, Manisha , Parrondo, Ricardo D , Freeman, Ciara L , Anderson, Larry D , Hosoya, Hitomi , Chhabra, Saurabh , Grajales-Cruz, Ariel F , Sborov, Douglas W , Patel, Krina , Hansen, Doris K , Costa, Luciano J , Merz, Maximilian , Sidana, Surbhi , Raza, Shahzad , Dhakal, Binod , Fandrei, David , Pan, Darren , Richard, Shambavi , Rees, Matthew J. , Costello, Patrick , Vazquez‐Martinez, Mariola , Pasvolsky, Oren , Puglianini, Omar Castañeda , Reshef, Ran , Dima, Danai , Nadeem, Omar , Chhabra, Saurabh , Grajales‐Cruz, Ariel , Gagelmann, Nico , Hansen, Doris K. , Costa, Luciano J. , Merz, Maximilian

Blood | August 1, 2025 | Volume: 146 | Issue: 17 | Pages: 2063-2072

10.1182/blood.2025029773 | PMID 40749169 Get It

Abstract Ciltacabtagene autoleucel (cilta-cel) and idecabtagene vicleucel (ide-cel), 2 B-cell maturation antigen (BCMA)–directed chimeric antigen receptor T-cell (CAR-T) therapies, have transformed outcomes for relapsed/refractory multiple myeloma; however, the 6 to 8 weeks manufacturing time risks disease progression or death in up to 10% of patients. Talquetamab, a G-protein–coupled receptor, family C, group 5, member D (GPRC5D)–targeting bispecific antibody, represents a promising option. We performed a multi-institutional retrospective analysis across 20 centers (18 United States, 2 Germany) evaluating talquetamab as a bridging therapy prior to cilta-cel or ide-cel. Among 134 patients receiving talquetamab, 119 proceeded to CAR-T (n = 98 cilta-cel, n = 21 ide-cel). Reasons for not proceeding (n = 15) included progression (n = 7), manufacturing failure (n = 6), or patient decision (n = 2). Median age was 65 years and had median 5 prior lines of therapy. Notably, 85% would not have met CARTITUDE-1/KarMMa eligibility criteria. Talquetamab was administered for a median 23 days. Toxicity was manageable: no grade ≥3 cytokine release syndrome (CRS), 2% grade 3 immune effector cell–associated neurotoxicity syndrome (ICANS) and grade 1 to 2 talquetamab unique toxicities (70% oral, 38% skin, and 17% nail; 60% resolved). Talquetamab achieved 71% response rate. After CAR-T, 88% responded (54% complete response), with low-grade toxicities (2 grade ≥3 CRS, 1 grade 3 ICANS, and 5% grade ≥3 infections). Two cases of facial palsy and 1 acute myeloid leukemia occurred. Talquetamab correlated with sustained soluble BCMA decline and peak CAR-T expansion around day 14. Talquetamab bridging appears safe, enabling the majority of difficult-to-treat patients to successfully proceed to BCMA CAR-T therapy.
Risk of Recurrent Ischemic Stroke in Patients With a Cardiac Thrombus
Nio, Shan Sui , Beemsterboer, Chiel F.P. , Goedman, Aletta F. , Planken, R. Nils , Coutinho, Jonathan M. , Rinkel, Leon A. , Beemsterboer, Chiel F P , Planken, R Nils , Coutinho, Jonathan M

Neurology Open Access | August 1, 2025 | Volume: 1 | Issue: 3 | Pages: No page available

10.1212/wn9.0000000000000030 Get It

A Hybrid CNN-GRU Model for Real-Time Prediction of Sepsis Clinical Trajectories in the ICU
Hou, Grace Yao , Hanson, Andrew C. , Schulte, Phillip J. , Lal, Amos , Dong, Yue , Gajic, Ognjen, Zhong, Xiang , Lal, Amos , Dong, Yue , Hou, Grace Yao

IEEE Robotics and Automation Letters | August 1, 2025 | Volume: 10 | Issue: 9 | Pages: 9565-9572

10.1109/lra.2025.3595040 Get It

Left Atrial Appendage Closure Versus Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation: An Updated Systematic Review and Meta-Analysis
Munir, Muhammad Bilal, Munir, Muhammad Bilal , Waqas, Muhammad , Munir, Muhammad Bilal , Naeem, Farhan , Qamar, Usama , Waqas, Muhammad Salman , Tabassum, Shehroze , Asad, Zain Ul Abideen

American Journal of Therapeutics | August 1, 2025 | Volume: 33 | Issue: 1 | Pages: e74-e77

10.1097/mjt.0000000000001992 | PMID 40748854 Get It

The value of deep inspirations
Sieck, Gary C. , Sieck, Gary

American Journal of Physiology-Lung Cellular and Molecular Physiology | August 1, 2025 | Volume: 329 | Issue: 3 | Pages: L341-L342

10.1152/ajplung.00249.2025 | PMID 40748703 Get It

Cardiovascular and aortic wave reflection responses to evening binge alcohol consumption
Thiverge, Grant S, Greenlund, Ian M. , Bigalke, Jeremy A. , Smoot, Carl A., Durocher, John J. , Carter, Jason R , Durocher, John J , Bigalke, Jeremy A , Thivierge, Grant S., Carter, Jason R.

American Journal of Physiology-Heart and Circulatory Physiology | August 1, 2025 | Volume: 329 | Issue: 3 | Pages: H629-H635

10.1152/ajpheart.00466.2025 | PMID 40748681 Get It

Increases in aortic wave reflection and aortic pulsatile load are known contributors to hypertension, cardiovascular risk, and pulsatile stress to end organs. To our knowledge, this is the first study to demonstrate that evening binge alcohol consumption increases heart rate, aortic pulsatile load, and aortic augmentation index the following morning when compared with fluid control. These findings highlight the deleterious overnight cardiovascular effects of binge alcohol consumption in young adults.
Successful Use of Corticosteroids to Accelerate Recovery in Severe Autoimmune-like Hepatitis From Isoniazid
Adeyi, Oyedele , Thomson, Mary , Seid, Amir Sultan, Adeyi, Oyedele , Sultan, Amir

ACG Case Reports Journal | August 1, 2025 | Volume: 12 | Issue: 8 | Pages: e01777

10.14309/crj.0000000000001777 | PMID 40757080 Get It

ABSTRACT Drug-induced autoimmune-like hepatitis represents a distinct phenotype of drug-induced liver injury characterized by clinical, biochemical, and/or histological features resembling autoimmune hepatitis. We present a case of severe Isoniazid (INH) -induced drug-induced autoimmune-like hepatitis in a 62-year-old man with a dramatic response to corticosteroid therapy after INH discontinuation alone proved insufficient. Initial laboratory tests showed markedly elevated transaminases and profound hyperbilirubinemia. Despite INH discontinuation, his clinical condition did not improve. Liver biopsy revealed severe acute hepatitis with interface hepatitis, lymphoplasmacytic infiltration, and multiple foci of lobular confluent necrosis. Prednisone therapy led to rapid clinical improvement and normalization of liver biochemistries over 3 months.